TMRW is revolutionizing in vitro fertilization with the first automated and robotic cryo-management platform devoted to IVF. By the end of the 21st century, more than 200 million children will have been born as a result of IVF. This medical triumph is anchored by advances in vitrification: the flash freezing of fertility cells at a temperature of -190 degrees Celsius. TMRW's cryo-management platform features 100% physical and digital chain-of-custody and continuous local and remote monitoring. TMRW brings peace of mind to clinicians and patients by provisioning up to 10,000 daily “health checks” on the environment surrounding the cryo-stored embryos and gametes under our care. The automation and digital controls of TMRW’s platform provide safe and efficient methods to store and track embryos and gametes, replacing the manual and error-prone processes that have, until now, been the industry norm. TMRW sets a new standard in IVF care and provides a core technology that will be instrumental in the birth of tens of millions of people worldwide. The TMRW team includes many of the world’s most celebrated pioneers in fertility, embryology, vitrification and cryo-management. The Founders have started both data science and medical device companies, the most recent of which were acquired for a combined value of more than $1 billion.

Attorney practicing healthcare, regulatory, nonprofit law, tax and tax-exempt institutions, estate planning. Began law career at Simpson Thacher & Bartlett.

Developed and led Merrill Lynch’s first healthcare institutional sales desk

Senior healthcare analyst for equity growth funds aggregating $15 billion; selected by portfolio manager to market funds nationwide